Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Investor Presentation (March 2025)
12 slides from Optomed Oyj Class A's investor presentation, March 2025
Slide 1: Revolutionizing Systemic Health Diagnostics with Handheld Devices
OPTOMED & OCULOMICS Revolutionizing Systemic Health Diagnostics with Handheld Devices Optomed Investor Presentation March, 2025
Slide 2: Oculomics: The Retina Offers Biomarkers for Systemic Health and Disease
Oculomics The Retina Offers Biomarkers for Systemic Health and Disease Diabetes and Blood Pressure Heart Calcium Score, Control, Nature Biomed Lancet Dig H, 2021 Engineering 2018 Alzheimer’s Disease, Lancet Dig Predicting Heart Attack and H, 2022 & Parkinson’s Disease, Stroke, Nature Mach Intel, Neu
Slide 3: Handheld Devices Are Perfect Fit for Oculomic Purposes
Handheld Devices Are Perfect Fit for Oculomic Purposes Optomed’s handheld Traditional equipment …together with AI camera… • Large initial investments • Saves real estate in • AI enables screening • Not usable in primary primary care settings of various conditions care due to space • Lower cost than
Slide 4: The only FDA-approved handheld with fully autonomous AI
The only FDA- approved hand- held with fully autonomous AI For the detection of more-than-mild DR from color fundus images • Macula-centered image; one per eye • No pupil dilation is needed (non-mydriatic) • Optomed Aurora IQ (Handheld) • Performance via 2 large-scale FDA prospective phase-III studi
Slide 5: Benefits to Healthcare Systems
Benefits to Healthcare Systems Revolutionize the way to treat diabetic eye disease Affordable • No start-up costs. Monthly rental fee and unlimited use. Scalable revenue growth • Billable code specific for DR screening with AI, CPT 92229. • Medicare National Average Reimbursement ~$401. Compliant •
Slide 6: Oculomic AI Roadmap
Oculomic AI Roadmap The markets for other diseases and preventive health-checks in primary care are significantly larger than the current ophthalmology market FUTURE: Preventive health-check in primary care Eye disease, neurological disorders, Alzheimer’s disease, cardiovascular Primary Care disease
Slide 7: Optomed is the leading solution provider for AI integrated handheld retinal imaging
Optomed is the leading solution provider for AI integrated handheld retinal imaging HQ and product development in Finland Revenue 15 MEUR (2024) Over 60 distributors in 50 countries; several OEM partners Own sales organisation and client base Office Outsourced Several AI partnerships e.g. manufactur
Slide 8: Transition to Recurring Revenue Model
Transition to Recurring Revenue Model Transition • Target market: Primary Care & Traditional Model Systemic Diseases • Handheld Device, Portal, and AI combined into a single oculomic • Target market: Ophthalmology & solution Eye Diseases • Solution leased on monthly fee basis • Capex sales via distr
Slide 9: investors@optomed.com www.optomed.com
investors@optomed.com www.optomed.com
Slide 10: 2024 Key Figures
2024 Key Figures 2024 2023 Change Revenue 15,040 15,100 -0.4% Gross profit 9,676 10,292 -6.0% Gross margin 64.3% 68.2% -38pps Adjusted EBITDA -2,796 -1,470 -90.2% Adjusted EBITDA margin -18.6% -9.7% -89pps Net profit / loss -5,450 -4,441 -22.7% Earnings per share -0.29 -0.27 -9.8% Cash flow from ope
Slide 11: Cash Flow 2024
Cash Flow 2024 2024 2023 Loss for the financial year -5,450 -4,441 Cash flows before change in net working capital -2,764 -1,491 Change in net working capital 1,254 1,137 Cash flows before finance items -1,510 -354 Cash flows from finance items -85 -262 Net cash from operating activities -1,596 -615
Slide 12: Balance Sheet
Balance Sheet 31 December 2024 31 December 2023 • Equity ratio of 74.4 (70.0) ASSETS percent Goodwill 4,256 4,256 Development costs 8,288 7,731 • Total borrowings of EUR Other intangible assets 1,421 1,759 Total intangible assets 13,965 13,746 2.3 (3.4) million Total tangible assets 652 710 Total no